ATE540111T1 - Hla-dr-bindendes antigenpeptid, das von wt1 abgeleitet ist - Google Patents

Hla-dr-bindendes antigenpeptid, das von wt1 abgeleitet ist

Info

Publication number
ATE540111T1
ATE540111T1 AT09003839T AT09003839T ATE540111T1 AT E540111 T1 ATE540111 T1 AT E540111T1 AT 09003839 T AT09003839 T AT 09003839T AT 09003839 T AT09003839 T AT 09003839T AT E540111 T1 ATE540111 T1 AT E540111T1
Authority
AT
Austria
Prior art keywords
peptide
hla
binding antigen
antigen peptide
peptide derived
Prior art date
Application number
AT09003839T
Other languages
English (en)
Inventor
Haruo Sugiyama
Original Assignee
Int Inst Cancer Immunology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Int Inst Cancer Immunology Inc filed Critical Int Inst Cancer Immunology Inc
Application granted granted Critical
Publication of ATE540111T1 publication Critical patent/ATE540111T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT09003839T 2003-11-05 2004-11-04 Hla-dr-bindendes antigenpeptid, das von wt1 abgeleitet ist ATE540111T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003375603 2003-11-05

Publications (1)

Publication Number Publication Date
ATE540111T1 true ATE540111T1 (de) 2012-01-15

Family

ID=34567081

Family Applications (1)

Application Number Title Priority Date Filing Date
AT09003839T ATE540111T1 (de) 2003-11-05 2004-11-04 Hla-dr-bindendes antigenpeptid, das von wt1 abgeleitet ist

Country Status (14)

Country Link
US (3) US20080070835A1 (de)
EP (2) EP1696027A4 (de)
JP (1) JP4621142B2 (de)
KR (3) KR101213015B1 (de)
CN (2) CN100513563C (de)
AT (1) ATE540111T1 (de)
CA (1) CA2544214C (de)
CY (1) CY1112585T1 (de)
DK (1) DK2071028T3 (de)
ES (1) ES2378264T3 (de)
PL (1) PL2071028T3 (de)
PT (1) PT2071028E (de)
SI (1) SI2071028T1 (de)
WO (1) WO2005045027A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030212B1 (en) * 1998-07-31 2006-04-18 Haruo Sugiyama Tumor antigen based on products of the tumor suppressor gene WT1
TWI318630B (en) 2001-03-22 2009-12-21 Int Inst Cancer Immunology Inc Wt1 modified peptide
JP5230891B2 (ja) * 2001-09-28 2013-07-10 株式会社癌免疫研究所 抗原特異的ｔ細胞の新規な誘導方法
US7342092B2 (en) * 2002-09-12 2008-03-11 International Institute Of Cancer Immunology, Inc. Cancer antigen peptide formulations
JP4498274B2 (ja) 2003-01-15 2010-07-07 株式会社癌免疫研究所 二量体化ペプチド
US10500257B2 (en) * 2003-06-27 2019-12-10 International Institute Of Cancer Immunology, Inc. Method of selecting WT1 vaccine adaptive patient
KR101213015B1 (ko) * 2003-11-05 2012-12-26 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 Ｗｔ１ 로부터 유도된 ｈｌａ-ｄｒ 결합성 항원 펩티드
EP2186896B1 (de) * 2004-03-31 2015-11-04 International Institute of Cancer Immunology, Inc. Von WT1 abgeleitete Krebs-Antigenpeptide
CA2626238C (en) 2005-10-17 2015-10-06 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
ES2352855T3 (es) * 2005-11-30 2011-02-23 International Institute Of Cancer Immunology, Inc. Nuevos compuestos peptídicos del tumor de wilms.
EP2010209B1 (de) 2006-04-10 2016-06-15 Sloan Kettering Institute For Cancer Research Immunogene wt-1-peptide und verfahren zu ihrer verwendung
NZ599161A (en) 2007-02-27 2012-07-27 Int Inst Cancer Immunology Inc Method for activation of helper t cell and composition for use in the method
JP5808079B2 (ja) 2007-03-05 2015-11-10 株式会社癌免疫研究所 癌抗原特異的ｔ細胞のレセプター遺伝子およびそれによりコードされるペプチドならびにそれらの使用
CN101854945B (zh) * 2007-09-18 2015-07-01 株式会社绿多肽 Ctl诱导剂组合物
WO2009066462A1 (ja) * 2007-11-20 2009-05-28 Nec Corporation 細胞傷害性ｔ細胞の誘導方法、細胞傷害性ｔ細胞の誘導剤、およびそれを用いた医薬組成物およびワクチン
AR076349A1 (es) * 2009-04-23 2011-06-01 Int Inst Cancer Immunology Inc Peptido auxiliar del antigeno del cancer
KR20140009168A (ko) * 2010-10-05 2014-01-22 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 헬퍼 ｔ 세포의 활성화 방법
EP3447140A3 (de) 2011-06-28 2019-05-29 International Institute of Cancer Immunology, Inc. Rezeptorgen für peptid-krebs-antigenspezifische t-zellen
WO2013018778A1 (ja) 2011-07-29 2013-02-07 独立行政法人理化学研究所 ウィルムス腫瘍遺伝子産物またはその断片をコードしている改変型核酸構築物を含んでいる免疫治療用細胞、当該細胞の製造方法、および当該核酸構築物
WO2013089252A1 (ja) * 2011-12-14 2013-06-20 国立大学法人 高知大学 ヘルパーｔ細胞誘導性ポリペプチドの改変
WO2013106834A2 (en) 2012-01-13 2013-07-18 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
RU2680588C2 (ru) 2012-09-12 2019-02-22 Интернешнл Инститьют Оф Кэнсер Иммунолоджи, Инк. Гены рецепторов антигенспецифичных хелперных т-клеток
CN104995203B (zh) 2012-12-17 2019-06-28 大塚制药株式会社 辅助性t细胞的活化方法
CA2896331C (en) 2012-12-26 2023-08-01 Oncosynergy, Inc. Anti-integrin .beta.1 antibody compositions and methods of use thereof
SI2945647T1 (sl) * 2013-01-15 2021-01-29 Memorial Sloan Kettering Cancer Center Imunogeni peptidi WT-1 in postopki za uporabo le-teh
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
CA2841016A1 (en) 2013-02-05 2014-08-05 Nitto Denko Corporation Wt1 peptide cancer vaccine composition for transdermal administration
CA2840941A1 (en) 2013-02-05 2014-08-05 Nitto Denko Corporation Wt1 peptide cancer vaccine composition for transdermal administration
KR102050931B1 (ko) 2013-02-05 2019-12-02 닛토덴코 가부시키가이샤 경피 투여용 ｗｔ1 펩티드 암 백신 테이프제
CN103961702B (zh) 2013-02-05 2019-04-09 日东电工株式会社 粘膜给予用wt1肽癌症疫苗组合物
EP3461493A1 (de) 2013-03-29 2019-04-03 Sumitomo Dainippon Pharma Co., Ltd. Wt1-antigen-peptid-konjugat-vakzin
US10588952B2 (en) 2013-03-29 2020-03-17 Sumitomo Dainippon Pharma Co., Ltd. Conjugate vaccine using trimming function of ERAP1
CN105378479A (zh) * 2013-05-13 2016-03-02 株式会社癌免疫研究所 用于预测免疫疗法的临床效果的方法
KR101804343B1 (ko) 2014-02-26 2017-12-04 텔라 가부시키가이샤 Ｗｔ１ 항원성 폴리펩티드 및 상기 폴리펩티드를 포함하는 항종양제
KR20170092660A (ko) * 2014-12-11 2017-08-11 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 혈관 신생병의 면역 요법
JP6699013B2 (ja) * 2014-12-25 2020-05-27 国立大学法人三重大学 Ｗｔ１由来ペプチド認識抗体
US20190381098A1 (en) * 2015-09-10 2019-12-19 Memorial Sloan Kettering Cancer Center Methods of treating multiple myeloma and plasma cell leukemia by t cell therapy
LT3377516T (lt) 2015-11-20 2022-09-26 Memorial Sloan Kettering Cancer Center Kompozicija vėžiui gydyti
CN109313201B (zh) * 2016-06-14 2022-04-01 高级生物设计公司 用于监测细胞凋亡的特异于γ-谷氨酰基-L-ε-赖氨酸(GGEL)的单克隆抗体
EP3549957A4 (de) 2016-11-30 2020-08-05 Sumitomo Dainippon Pharma Co., Ltd. Wt1-helferpeptid und kombination des besagten peptids und eines krebsantigen-peptidkonjugats
KR200491679Y1 (ko) 2017-02-14 2020-06-03 정찬회 색칠 팔레트 교구
EP3604325A4 (de) 2017-03-30 2021-01-13 Sumitomo Dainippon Pharma Co., Ltd. Wt1-krebs-antigen-peptid und peptid-konjugat-körper damit
CN110709424B (zh) 2017-05-31 2024-01-05 科济生物医药（上海）有限公司 细胞免疫治疗的组合物和方法
CN113382746A (zh) 2018-09-28 2021-09-10 大日本住友制药株式会社 注射用组合物
TW202045528A (zh) 2019-02-28 2020-12-16 日商大日本住友製藥股份有限公司 選擇可期待用於治療或預防癌之醫藥組合物之效果之對象之方法
AU2020322246A1 (en) * 2019-07-30 2022-03-03 University Health Network MHC class II molecules and methods of use thereof
CA3182959A1 (en) 2020-05-12 2021-11-18 Sumitomo Pharma Co., Ltd. Pharmaceutical composition for treating cancer
AU2022327884A1 (en) 2021-08-12 2024-02-22 International Institute Of Cancer Immunology, Inc. Pharmaceutical composition and method for treatment or prevention of cancer

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5726288A (en) * 1989-11-13 1998-03-10 Massachusetts Institute Of Technology Localization and characterization of the Wilms' tumor gene
US7030212B1 (en) 1998-07-31 2006-04-18 Haruo Sugiyama Tumor antigen based on products of the tumor suppressor gene WT1
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7063854B1 (en) 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
ATE399179T1 (de) * 1998-09-30 2008-07-15 Corixa Corp Zusammensetzungen und verfahren für wt1- spezifische immunotherapie
WO2001002142A1 (en) * 1999-07-07 2001-01-11 North American Tire Research And Recycling Tire cutting machine and method
EP1261711A2 (de) * 2000-02-22 2002-12-04 Corixa Corporation Zusammensetzungen und methoden zur diagnose und therapie von malignen mesotheliom
AU2002222610A1 (en) 2000-12-13 2002-06-24 Sumitomo Pharmaceuticals Company, Limited Transgenic animal expressing hla-a24 and utilization thereof
TWI318630B (en) 2001-03-22 2009-12-21 Int Inst Cancer Immunology Inc Wt1 modified peptide
GB0108491D0 (en) 2001-04-04 2001-05-23 Gendaq Ltd Engineering zinc fingers
DE60238958D1 (de) 2001-06-29 2011-02-24 Chugai Pharmaceutical Co Ltd Krebsimpfstoff mit einem Krebs-Antigen auf Grundlage des Produkts aus dem Tumorunterdrückungsgen WT1 und einem kationischen Liposom
WO2003028758A1 (fr) * 2001-09-28 2003-04-10 Haruo Sugiyama Nouvelle methode d'induction de lymphocytes t specifiques d'un antigene
JP5230891B2 (ja) 2001-09-28 2013-07-10 株式会社癌免疫研究所 抗原特異的ｔ細胞の新規な誘導方法
CN101113163B (zh) 2002-06-12 2010-10-06 株式会社国际癌症免疫研究所 Hla-a24限制性癌抗原肽
US7342092B2 (en) 2002-09-12 2008-03-11 International Institute Of Cancer Immunology, Inc. Cancer antigen peptide formulations
JP4480580B2 (ja) 2002-09-20 2010-06-16 株式会社癌免疫研究所 Ｗｔ１置換型ペプチド
JP4498274B2 (ja) 2003-01-15 2010-07-07 株式会社癌免疫研究所 二量体化ペプチド
US10500257B2 (en) 2003-06-27 2019-12-10 International Institute Of Cancer Immunology, Inc. Method of selecting WT1 vaccine adaptive patient
KR101213015B1 (ko) 2003-11-05 2012-12-26 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 Ｗｔ１ 로부터 유도된 ｈｌａ-ｄｒ 결합성 항원 펩티드
EP2186896B1 (de) 2004-03-31 2015-11-04 International Institute of Cancer Immunology, Inc. Von WT1 abgeleitete Krebs-Antigenpeptide
JP4719876B2 (ja) 2005-04-04 2011-07-06 国立大学法人愛媛大学 Ｈｌａクラスｉｉ拘束性ｗｔ１抗原ペプチド
CA2626238C (en) 2005-10-17 2015-10-06 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
JP5200541B2 (ja) 2005-10-24 2013-06-05 日本電気株式会社 分布型増幅器、集積回路および送受信器
ES2352855T3 (es) 2005-11-30 2011-02-23 International Institute Of Cancer Immunology, Inc. Nuevos compuestos peptídicos del tumor de wilms.
US8759483B2 (en) 2006-02-22 2014-06-24 International Institute Of Cancer Immunology, Inc. HLA-A* 3303-restricted WT1 peptide and pharmaceutical composition comprising the same
EP2010209B1 (de) 2006-04-10 2016-06-15 Sloan Kettering Institute For Cancer Research Immunogene wt-1-peptide und verfahren zu ihrer verwendung
NZ592510A (en) 2006-12-28 2012-11-30 Int Inst Cancer Immunology Inc HLA-A*1101-restricted WTI peptide and pharmaceutical composition comprising the same
NZ599161A (en) 2007-02-27 2012-07-27 Int Inst Cancer Immunology Inc Method for activation of helper t cell and composition for use in the method
JP5808079B2 (ja) 2007-03-05 2015-11-10 株式会社癌免疫研究所 癌抗原特異的ｔ細胞のレセプター遺伝子およびそれによりコードされるペプチドならびにそれらの使用
AR076349A1 (es) 2009-04-23 2011-06-01 Int Inst Cancer Immunology Inc Peptido auxiliar del antigeno del cancer
KR20140009168A (ko) 2010-10-05 2014-01-22 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 헬퍼 ｔ 세포의 활성화 방법
CN104995203B (zh) 2012-12-17 2019-06-28 大塚制药株式会社 辅助性t细胞的活化方法

Also Published As

Publication number Publication date
SI2071028T1 (sl) 2012-03-30
CN101580538B (zh) 2013-06-19
KR101522079B1 (ko) 2015-05-21
US20180207254A1 (en) 2018-07-26
ES2378264T3 (es) 2012-04-10
WO2005045027A1 (ja) 2005-05-19
KR20060123756A (ko) 2006-12-04
US11027003B2 (en) 2021-06-08
JPWO2005045027A1 (ja) 2007-05-17
US20080070835A1 (en) 2008-03-20
CN101580538A (zh) 2009-11-18
KR20130062368A (ko) 2013-06-12
CA2544214A1 (en) 2005-05-19
CA2544214C (en) 2018-08-28
KR101213015B1 (ko) 2012-12-26
EP2071028B1 (de) 2012-01-04
DK2071028T3 (da) 2012-03-05
CY1112585T1 (el) 2016-02-10
EP2071028A3 (de) 2009-06-24
KR20120067374A (ko) 2012-06-25
JP4621142B2 (ja) 2011-01-26
EP2071028A2 (de) 2009-06-17
PT2071028E (pt) 2012-04-10
PL2071028T3 (pl) 2012-06-29
US10124046B2 (en) 2018-11-13
CN1902313A (zh) 2007-01-24
CN100513563C (zh) 2009-07-15
EP1696027A1 (de) 2006-08-30
US20130243800A1 (en) 2013-09-19
EP1696027A4 (de) 2008-05-14

Similar Documents

Publication Publication Date Title
ATE540111T1 (de) Hla-dr-bindendes antigenpeptid, das von wt1 abgeleitet ist
CY1113650T1 (el) Συντηρημενα αντιγονα neisseria
CY1106875T1 (el) Αντιγονικα πεπτιδια απο neisseria
ATE540973T1 (de) Zusammensetzungen und verfahren zur verwendung von mgd-cdf zur krankheitsbehandlung
DK1548032T3 (da) KDR-peptider og vacciner indeholdende disse
ATE477272T1 (de) Verwendung von stefin a als gerüstprotein
HUP9902571A2 (hu) Timidin kináz variánsai, ezeket kódoló nukleinsav-szekvenciák és alkalmazásuk génterápiában
ATE368688T1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
DE60335726D1 (de) Chromoprotein und fluoroproteine
EP1071443A4 (de) Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
ES2145061T3 (es) Diagnostico y terapia a base de peptidos para el tratamiento de las espondiloartropatias.
DE59410423D1 (de) Serin-threonin-kinase enthaltendes mittel zur tumortherapie und tumordiagnose
ATE346091T1 (de) Neues diagnostisches reagens und kit zur erkennung von rickettsiose
DE602004026466D1 (de) Neue mittel zur prävention von leishmaniose
DE60234843D1 (de) Modifizierte peptide und deren verwendung zur behandlung von autoimmunkrankheiten
ATE366810T1 (de) Menschliche p51-gene und deren genprodukte
DK0811068T3 (da) Humane DNase I varianter
WO2003064446A3 (en) Plasma protein-binding peptides from bacterial curli
ATE427355T1 (de) Menschliche alpha2-delta4-calciumkanal- untereinheit codierende cdna
ATE427955T1 (de) Zusammensetzungen und verfahren zur erfassung von stress induzierten proteinen
WO2001081413A3 (en) Isolated human transporter proteins, nucleic acids and uses thereof
HUP0203080A2 (hu) A PRV-1 gén és felhasználása
DE60129228D1 (de) Humane 7-transmembranproteine und dafür codierende polynukleotide
BR0107799A (pt) Proteìna de interação de wt1 wtip
WO2002064628A3 (en) Isolated human transporter proteins nucleic acids and use thereof